{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10","upperLimit":"26","value":"16"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"}],"units":"Participants"}],"description":"To establish the time to engraftment of myeloma patients treated with high dose melphalan, APBSCT\\& adoptive transfer of cytotoxic effector cells with IL-2 and GM-CSF.","dispersionType":"Full Range","groups":[{"description":"Infusing IL-2 and GM-CSF post-HCST\n\nEx-vivo expanded effector cells: This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.","id":"OG000","title":"Ex-vivo Expanded Effector Cells"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"From initiation of treatment on protocol until Day 100","title":"Time to Recovery of Platelet Count","type":"SECONDARY","unitOfMeasure":"days"}